Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Oct;32(10):1796-801.
doi: 10.2337/dc09-0676. Epub 2009 Jul 8.

Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme-1 (IDPP-1)

Chamukuttan Snehalatha  1 , Simon Mary, Sundaram Selvam, Cholaiyil Kizhakathil Sathish Kumar, Samith Babu Ananth Shetty, Arun Nanditha, Ambady Ramachandran
Affiliations
Randomized Controlled Trial

Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme-1 (IDPP-1)

Chamukuttan Snehalatha et al. Diabetes Care. 2009 Oct.

Abstract

Objective: The Indian Diabetes Prevention Programme-1 (IDPP-1) showed that lifestyle modification (LSM) and metformin were effective for primary prevention of diabetes in subjects with impaired glucose tolerance (IGT). Among subjects followed up for 3 years (n = 502), risk reductions versus those for the control group were 28.5, 26.4, and 28.2% in LSM, metformin (MET), and LSM plus MET groups, respectively. In this analysis, the roles of changes in secretion and action of insulin in improving the outcome were studied.

Research design and methods: For this analysis, 437 subjects (93 subjects with normoglycemia [NGT], 150 subjects with IGT, and 194 subjects with diabetes) were included. Measurements of anthropometry, plasma glucose, and plasma insulin at baseline and at follow-up were available for all of them. Indexes of insulin resistance (homeostasis model assessment of insulin resistance) and beta-cell function (insulinogenic index [DeltaI/G]: 30-min fasting insulin divided by 30-min glucose) were also analyzed in relation to the outcome.

Results: Subjects with IGT showed a deterioration in beta-cell function with time. Individuals with higher insulin resistance and/or low beta-cell function at baseline had poor outcome on follow-up. In relation to no abnormalities, the highest incidence of diabetes occurred when both abnormalities coexisted (54.9 vs. 33.7%, chi(2) = 7.53, P = 0.006). Individuals having abnormal insulin resistance (41.1%) or abnormal DeltaI/G (51.2%, chi(2) = 4.87, P = 0.027 vs. no abnormalities) had lower incidence. Normal beta-cell function with improved insulin sensitivity facilitated reversal to NGT, whereas deterioration in both resulted in diabetes. The beneficial changes were better with intervention than in the control group. Intervention groups had higher rates of NGT and lower rates of diabetes.

Conclusions: In the IDPP-1 subjects, beneficial outcomes occurred because of improved insulin action and sensitivity caused by the intervention strategies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Median values of HOMA-IR (A, left panel) and ΔI/G (A, right panel) were calculated in relation to glycemic status (NGT, IGT [B], and diabetes [C]) at annual follow-up. The median values at the 1st-, 2nd-, and 3rd-year follow-up in comparison with the corresponding baseline values in these participants are shown in each category of glucose tolerance. A: 1st year n = 160, 2nd year n = 155, 3rd year n = 93. B: 1st year n = 201, 2nd year n = 152, 3rd year n = 150. C: 1st year n = 70, 2nd year n = 60, 3rd year n = 64. ▩, baseline; ▨, follow-up. *P < 0.05 vs. baseline values.
See this image and copyright information in PMC

References

    1. Tumilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Loutheranta A, Rastas M, Salminen V, Uusitupa M: the Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343–1350 - PubMed
    1. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. Diabetes Prevention Program Research Group. N Engl J Med 2002;346:393–403 - PMC - PubMed
    1. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537–544 - PubMed
    1. Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, Li H, Li H, Jiang Y, An Y, Shuai Y, Zhang B, Zhang J, Thompson TJ, Gerzoff RB, Roglic G, Hu Y, Bennett PH: The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008;371:1783–1789 - PubMed
    1. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V: The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006;49:289–297 - PubMed

Publication types